Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600135004) titled 'Efficacy and safety of a dual GIP and GLP-1 receptor agonist in patients with obesity or overweight: a multicentre, randomised, controlled trial' on Oct. 22.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Zhongda Hospital Southeast University
Condition:
Obesity or overweight accompanied by at least one weight-related comorbidity
Intervention:
tirzepatide combined with lifestyle intervention group:tirzepatide combined with lifestyle intervention
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-22
Target Sample Size: tirzepatide combined with lif...